Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
ConditionEpidermolysis Bullosa Dystrophica
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorStanford University
About this trial
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinical diagnosis of RDEB by local dermatologist
7 years of age or older
Disqualifiers
None
Trial population
Patients diagnosed with RDEB by a local dermatologist who are medically stable enough to travel to Stanford University Medical Center. Patients should also be at least 7 years of age.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa for future studies
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov